Scholarlink

Background and Objectives <p>Tranexamic acid (TXA), a synthetic antifibrinolytic agent, offers considerable promise as a potential therapy to improve postoperative outcomes for patients undergoing breast surgery. However, its specific role in plastic breast surgery remains understudied. Hence, we aimed to evaluate its efficacy in cosmetic plastic breast surgery.</p> Methods <p>An extensive literature search of electronic databases such as PubMed, Embase, and Cochrane CENTRAL was conducted from inception to October 2023. Quality assessment of the included studies was done using the Newcastle–Ottawa scale (NOS). The results of our analyses were presented as odds ratios (ORs) with 95% confidence intervals (CIs) and pooled using a random effects model. A <i>p</i>-value &lt; 0.05 was considered significant in all cases.</p> Results <p>A total of 8 studies, encompassing 2311 participants were included in our analysis. The pooled analysis demonstrates that TXA is associated with a significant improvement in hematoma formation (OR 0.37, 95% CI: 0.24–0.58; <i>p</i>&#xa0;&lt;&#xa0;0.0001). There was no significant improvement in seroma formation (OR 0.65, 95% CI: 0.33–1.27; <i>p</i>&#xa0;=&#xa0;0.21), infection rate (OR 1.84, 95% CI: 0.49–6.94; <i>p</i>&#xa0;=&#xa0;0.37) or partial loss of the nipple–areolar complex (OR 0.47, 95% CI: 0.12–1.82; <i>p</i>&#xa0;=&#xa0;0.28).</p> Conclusion <p>Tranexamic acid demonstrated considerable efficacy in improving postoperative outcomes for patients undergoing cosmetic and reconstructive breast surgeries.</p> Level of Evidence I <p>This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to&#xa0;Authors <a href="http://www.springer.com/00266">www.springer.com/00266</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tranexamic Acid for Postoperative Outcomes in Breast Plastic Surgery: A Systematic Review and Meta-analysis

  • 期刊论文

  • 发表日期：

    2025年3月17日

查看全文
  • Mohammed A. Althobaiti,
  • Muhammad Talha Maniya,
  • Rakan H. Alelyani,
  • Sabeeh Khawar Farooqui,
  • Abdulaziz Saud Aljuaid,
  • Zainb Mohammed Alfarej,
  • Ahmed Abdullah Almenhali,
  • Fahad K. Aljindan

摘要

Background and Objectives

Tranexamic acid (TXA), a synthetic antifibrinolytic agent, offers considerable promise as a potential therapy to improve postoperative outcomes for patients undergoing breast surgery. However, its specific role in plastic breast surgery remains understudied. Hence, we aimed to evaluate its efficacy in cosmetic plastic breast surgery.

Methods

An extensive literature search of electronic databases such as PubMed, Embase, and Cochrane CENTRAL was conducted from inception to October 2023. Quality assessment of the included studies was done using the Newcastle–Ottawa scale (NOS). The results of our analyses were presented as odds ratios (ORs) with 95% confidence intervals (CIs) and pooled using a random effects model. A p-value < 0.05 was considered significant in all cases.

Results

A total of 8 studies, encompassing 2311 participants were included in our analysis. The pooled analysis demonstrates that TXA is associated with a significant improvement in hematoma formation (OR 0.37, 95% CI: 0.24–0.58; p < 0.0001). There was no significant improvement in seroma formation (OR 0.65, 95% CI: 0.33–1.27; p = 0.21), infection rate (OR 1.84, 95% CI: 0.49–6.94; p = 0.37) or partial loss of the nipple–areolar complex (OR 0.47, 95% CI: 0.12–1.82; p = 0.28).

Conclusion

Tranexamic acid demonstrated considerable efficacy in improving postoperative outcomes for patients undergoing cosmetic and reconstructive breast surgeries.

Level of Evidence I

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.